3상모집 중단 (진행 중)
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
연구 개요
The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the BRAFV600E mutation, who are refractory to radioactive iodine (RAI) therapy and have experienced disease progression following one or two prior VEGFR-targeted treatments.
- 스폰서
- 리드: 노바티스
- 적응증
- Differentiated Thyroid Cancer (DTC)
- 중재
- Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo
- 목표 등록
- 153명
- 시작일
- 2021-11-15
- 완료(예정)
- 2027-05-25
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.